eJHaem (Jul 2020)
Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study
- Konstantinos Liapis,
- Georgios Vrachiolias,
- Vasileios Papadopoulos,
- Alexandra Kourakli,
- Athanasios G. Galanopoulos,
- Menelaos Papoutselis,
- Sotirios G. Papageorgiou,
- Panagiotis T. Diamantopoulos,
- Vassiliki Pappa,
- Nora‐Athina Viniou,
- Theodoros P. Vassilakopoulos,
- Eleftheria Hatzimichael,
- Eleni Bouronikou,
- Maria Ximeri,
- Charalambos Pontikoglou,
- Panayiotis Panayiotidis,
- Stamatis Karakatsanis,
- Anna Vardi,
- Argiris Symeonidis,
- Ioannis Kotsianidis
Affiliations
- Konstantinos Liapis
- Department of Hematology Democritus University of Thrace Medical School Alexandroupolis Greece
- Georgios Vrachiolias
- Department of Hematology Democritus University of Thrace Medical School Alexandroupolis Greece
- Vasileios Papadopoulos
- Department of Hematology Democritus University of Thrace Medical School Alexandroupolis Greece
- Alexandra Kourakli
- Department of Internal Medicine University Hospital of Patras Rio Greece
- Athanasios G. Galanopoulos
- Department of Clinical Hematology Georgios Gennimatas Hospital Athens Greece
- Menelaos Papoutselis
- Department of Hematology Democritus University of Thrace Medical School Alexandroupolis Greece
- Sotirios G. Papageorgiou
- Second Department of Internal Medicine Attikon University General Hospital Athens Greece
- Panagiotis T. Diamantopoulos
- First Department of Internal Medicine National and Kapodistrian University of Athens Athens Greece
- Vassiliki Pappa
- Second Department of Internal Medicine Attikon University General Hospital Athens Greece
- Nora‐Athina Viniou
- First Department of Internal Medicine National and Kapodistrian University of Athens Athens Greece
- Theodoros P. Vassilakopoulos
- Department of Hematology Laikon General Hospital National and Kapodistrian University of Athens Athens Greece
- Eleftheria Hatzimichael
- Department of Hematology University Hospital of Ioannina Ioannina Greece
- Eleni Bouronikou
- Department of Hematology University Hospital of Larissa Larissa Greece
- Maria Ximeri
- Department of Hematology University General Hospital of Heraklion Heraklion Greece
- Charalambos Pontikoglou
- Department of Hematology University General Hospital of Heraklion Heraklion Greece
- Panayiotis Panayiotidis
- First Propaedeutic Department of Internal Medicine National and Kapodistrian University of Athens Athens Greece
- Stamatis Karakatsanis
- Department of Hematology Sotiria General Hospital Athens Greece
- Anna Vardi
- Department of Hematology and Stem Cell Transplantation Georgios Papanicolaou General Hospital Thessaloniki Greece
- Argiris Symeonidis
- Department of Internal Medicine University Hospital of Patras Rio Greece
- Ioannis Kotsianidis
- Department of Hematology Democritus University of Thrace Medical School Alexandroupolis Greece
- DOI
- https://doi.org/10.1002/jha2.30
- Journal volume & issue
-
Vol. 1,
no. 1
pp. 255 – 261
Abstract
Abstract Cardiovascular disease (CVD) emerges as a major cause of death in patients with myelodysplastic syndrome (MDS), but predictors of fatal CVD and the effect of MDS‐specific treatments on CVD mortality remain largely unknown. In an analysis involving 831 patients with MDS with known causes of death, we noted an independent association of lower risk MDS, age >70 years, pre‐existing CVD, and treatment with erythropoiesis‐stimulating agents with a higher risk of death from CVD. If externally validated, these simple risk factors could increase clinicians’ awareness toward CVD complications and guide early introduction of intensive monitoring and preventive interventions in MDS patients.
Keywords
- cardiovascular disease
- coronary heart disease
- death
- erythropoiesis‐stimulating agents
- mortality
- myelodysplastic syndromes
